Welcome to our dedicated page for Inmed Pharmaceuticals news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on Inmed Pharmaceuticals stock.
InMed Pharmaceuticals Inc. (NASDAQ: INM) is a pharmaceutical drug development company that regularly issues news and updates about its proprietary small molecule programs and related corporate activities. The company focuses on drug candidates targeting the CB1/CB2 receptors in three main therapeutic areas: Alzheimer’s disease, ocular conditions and dermatological indications, and it also reports on the commercial operations of its rare cannabinoid subsidiary BayMedica.
News about InMed often covers progress in its lead Alzheimer’s program INM-901, including preclinical data, pharmacokinetic studies in animal models and scientific presentations at major conferences such as the Alzheimer’s Association International Conference (AAIC). Releases describe how INM-901 is being evaluated across multiple biological pathways associated with Alzheimer’s disease and summarize findings from long-term studies in established disease models.
Investors and followers of INM can also find updates on INM-089, a proprietary small molecule drug candidate under investigation for dry age-related macular degeneration, including preclinical study results and formulation work for intravitreal delivery. In addition, InMed provides business updates on BayMedica, including sales performance, legislative developments affecting rare, non-intoxicating cannabinoids and the subsidiary’s evaluation of alternative supply chain options to maintain regulatory compliance.
Corporate and capital markets developments are another frequent theme in InMed’s news flow. The company announces private placements, preferred investment option amendments, participation in investor conferences, and changes to its board of directors, as well as the outcomes of its annual general and special meetings of shareholders. For readers tracking INM news, this page offers a centralized view of scientific, commercial, financial and governance announcements directly tied to the company’s disclosed activities.
InMed Pharmaceuticals (NASDAQ: INM) has announced a $5 million private placement with a single institutional investor. The company will issue 1,952,363 common shares (or pre-funded warrants) and short-term preferred investment options at $2.561 per share.
The offering includes short-term preferred investment options exercisable at $2.436 per share, expiring 18 months after the Resale Registration Statement's effective date. If fully exercised, these options could generate additional proceeds of $4.75 million. The company will use funds for pipeline development, supporting BayMedica LLC's commercial sales, and working capital.
Additionally, InMed will amend existing preferred investment options from October 2023, reducing the exercise price from $16.60 to $2.436 per share.
InMed Pharmaceuticals (NASDAQ: INM) has announced promising preclinical results for INM-901, their therapeutic candidate for Alzheimer's disease. In an ex vivo study, INM-901 demonstrated significant reduction of neuroinflammation in animal brain tissue.
The study revealed that INM-901 significantly reduced levels of key inflammatory markers, including NLRP3, IL-6, IL-1β, KC/Gro, and IL-2. Notably, these anti-inflammatory effects were achieved independently of amyloid beta or tau pathology, suggesting potential applications in various dementia-related diseases.
INM-901's key characteristics include oral administration capability, neuroprotective effects through CB1/CB2 receptor interaction, and demonstrated improvements in cognitive function and memory in preclinical studies. The company plans to advance INM-901 through additional preclinical studies, followed by IND-enabling studies.
InMed Pharmaceuticals (NASDAQ: INM) reported Q2 FY2025 financial results, posting a net loss of $2.6M compared to $1.5M in the same period last year. The company's BayMedica commercial unit generated revenues of $1.1M, a 10% decrease from the previous year, but achieved a net income of $0.23M, representing a 189% improvement.
Key developments include positive results from INM-901's preclinical Alzheimer's disease study, showing reduction in neuroinflammatory markers, and the selection of an intravitreal formulation for INM-089 in dry AMD treatment. The company's cash position stood at $3.5M as of December 31, 2024, with an additional $2.9M raised in January 2025, expected to fund operations through Q2 2025.
Operating expenses increased with R&D costs rising to $1M from $0.6M, and G&A expenses reaching $1.6M compared to $1.4M in the previous year.
InMed Pharmaceuticals (NASDAQ: INM) has announced the selection of an intravitreal (IVT) formulation for INM-089 as a drug candidate for treating dry age-related macular degeneration (AMD). The company has achieved successful delivery of the formulation at doses up to 10 times the projected therapeutic level, demonstrating a favorable pharmacokinetic profile and significant safety margin.
The company has completed dose-ranging in vivo studies, which will guide the selection of appropriate doses for pivotal preclinical toxicology studies. The INM-089 IVT formulation will proceed to GLP-enabling studies and subsequent clinical development stages. InMed chose intravitreal injection as the delivery method, noting it's the established standard of care among retinal specialists, particularly given the challenges of delivering lipophilic drugs through topical formulations like eye drops.
InMed Pharmaceuticals (NASDAQ: INM) has been granted its first international Patent Cooperation Treaty (PCT) patent in Mexico for novel cannabinoid analog compounds. The patent, titled 'Cannabinoid analogs and methods for their preparation', has a 20-year term and covers therapeutic applications for pain, glaucoma, inflammatory disease, anxiety, and neurological conditions including Parkinson's and Alzheimer's disease.
The patent protects both the compounds and their preparation methods, including drug candidates for Alzheimer's disease and dry age-related macular degeneration programs. The PCT application is pending in several additional jurisdictions including the U.S., Europe, and Japan. InMed currently maintains 14 patent families covering compositions, formulations, manufacturing processes, and methods of use.
InMed Pharmaceuticals (NASDAQ: INM) has announced positive results from a long-term preclinical Alzheimer's Disease study of INM-901. The drug candidate demonstrated significant reductions in several neuroinflammation markers:
- Dose-dependent and statistically significant reduction in plasma pro-inflammatory cytokines (TNF-α, IL-1β, INF-γ)
- Significant reduction in neurofilament light chain (NfL), a neurodegeneration biomarker
- Reduced expression of key neuroinflammatory genes (GFAP, CD-33, TLR-2) in the brain
INM-901's key characteristics include oral administration capability, demonstrated neuroprotective effects through CB1/CB2 receptor activation, and impact on PPARs. The company is conducting additional analyses focusing on receptor engagement levels, neuritogenesis, and neuroprotection, with results expected in the coming weeks.
InMed Pharmaceuticals (NASDAQ: INM) held its 2024 annual general meeting on December 18, where shareholders voted on key matters. 39.83% of the company's 13,353,431 outstanding shares were represented at the meeting. Four director nominees were approved, while Ms. Janet Grove's election was withheld with 55.74% votes against. In accordance with the Company's Majority Voting Policy, Ms. Grove has offered her resignation, which will be reviewed by the Nominating & Governance Committee. Shareholders also approved Marcum LLP (now CBIZ LLP) as the company's auditors for the following year.
InMed Pharmaceuticals (NASDAQ: INM) has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, , managed by Yorkville Advisors Global LP, on December 13, 2024. The agreement allows InMed to sell up to $10 million of common shares over a 36-month period.
The shares will be priced at 97% of the Market Price during a specified three-day pricing period. The total shares issuable are to 19.99% of outstanding shares as of the effective date, and the Investor's beneficial ownership cannot exceed 9.99%. InMed maintains the right to set minimum acceptable prices for share issuances.